OCV 501

Drug Profile

OCV 501

Alternative Names: OCV-501

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator International Institute of Cancer Immunology
  • Developer Otsuka Pharmaceutical
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 22 Feb 2016 Otsuka completes enrolment in a phase II trial for Acute myeloid leukaemia (In the elderly, Prevention of relapse) in Japan, South Korea and Taiwan (NCT01961882)
  • 08 Jun 2015 Phase-II clinical development is ongoing in Japan, South Korea and Taiwan.
  • 31 Oct 2014 Phase-II clinical trials in Acute myeloid leukaemia (In the elderly, Prevention of relapse) in South Korea and Taiwan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top